AstraZeneca 2010 third quarter decreases 2% to $7,898 million

Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for the third quarter declined by 2% at constant exchange rates (CER) to $7,898 million. Strong double-digit sales growth at CER for Crestor, Symbicort and Seroquel XR. Revenue in markets outside the US increased by 7% at CER, including a 14% increase in Emerging Markets.

As expected, revenue in the US was affected by generic competition for Arimidex, Pulmicort Respules and Toprol-XL, as well as the absence of H1N1 pandemic influenza vaccine revenue that benefited the third quarter 2009. US revenue was down 13% in the third quarter. Available video includes headquarters, laboratory and production shots